标题
Ataluren in cystic fibrosis: development, clinical studies and where are we now?
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume 18, Issue 13, Pages 1363-1371
出版商
Informa UK Limited
发表日期
2017-07-22
DOI
10.1080/14656566.2017.1359255
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids
- (2016) D.D. Zomer-van Ommen et al. Journal of Cystic Fibrosis
- Cystic fibrosis
- (2016) J Stuart Elborn LANCET
- Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression
- (2016) Bijoyita Roy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Translating the genetics of cystic fibrosis to personalized medicine
- (2016) Harriet Corvol et al. Translational Research
- Future trends in cystic fibrosis demography in 34 European countries
- (2015) Pierre-Régis Burgel et al. EUROPEAN RESPIRATORY JOURNAL
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
- (2015) Claire E. Wainwright et al. NEW ENGLAND JOURNAL OF MEDICINE
- Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets
- (2015) Iram J Haq et al. THORAX
- The relative frequency of CFTR mutation classes in European patients with cystic fibrosis
- (2014) K. De Boeck et al. Journal of Cystic Fibrosis
- Ataluren treatment of patients with nonsense mutation dystrophinopathy
- (2014) Katharine Bushby et al. MUSCLE & NERVE
- Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Eitan Kerem et al. Lancet Respiratory Medicine
- Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with aG551DMutation
- (2013) Jane C. Davies et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays
- (2013) Stuart P. McElroy et al. PLOS BIOLOGY
- Drug bests cystic-fibrosis mutation
- (2012) Heidi Ledford NATURE
- Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis
- (2011) M. Wilschanski et al. EUROPEAN RESPIRATORY JOURNAL
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation
- (2011) Bonnie W. Ramsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis
- (2010) Isabelle Sermet-Gaudelus et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression
- (2009) D. S. Auld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
- (2009) F. Van Goor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial
- (2008) Eitan Kerem et al. LANCET
- PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model
- (2008) M. Du et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search